Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, said, "We are excited to have Lucy join the Coronado management team. With more than 10 years experience as a Wall Street biotechnology analyst and investment banker, Lucy has a strong financial background and a comprehensive understanding of the drug development process. This valuable knowledge and expertise will be crucial to our organization as we move our TSO and CNDO-109 programs through clinical development to commercialization."
Most recently, Dr. Lu was a Senior Biotechnology Analyst at Citigroup Investment Research where she was responsible for the coverage of small and middle capitalization stocks and the vetting of both public and private companies. Prior to Citigroup, Dr. Lu worked in equity research at First Albany Capital as a Vice President and Principal. She started her career at Lehman Brothers as an Associate of Healthcare Investment Banking.
"I believe that Coronado's pipeline candidates have the potential to be transformative treatments for patients with certain autoimmune conditions and cancer, and I am thrilled to be part of this team," stated Dr. Lu.
Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT: Investor Relations
Noah D. Beerman
Executive Vice President & Chief Operating Officer
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com
Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159; dobsonpr@erols.com
